Dr
Frank, Chia-Jung
Chang
Dr
Frank, Chia-Jung
Chang
Chief Technology Officer
Reber Genetics Co., Ltd.
Biography
Dr. Frank Chia-Jung Chang obtains his Ph.D. from Life Science and Institute of Genome Science department of Taiwan Yang-Ming Medical University in 2012. He received his postdoctoral training at Molecular Biology Institute of Academia Sinica (Taiwan) and worked as visiting scholar in Frances H. Arnold’s laboratory (Nobel Prize in Chemistry winner in 2018), Chemical Engineering Department of Caltech (U.S.). He joined Reber Genetics as the supervisor of R&D Division in 2014. From 2017, Frank also works for business development and strategic layout of vaccine products (technology included). Dr. Chang has considerable expertise in virology, microbiology, reverse vaccinology and protein engineering for industrial production. His group has successfully developed novel subunit vaccines of swine PRRSV, pan-PCV, Mycoplasma, CSFV and PEDV in Reber Genetics, furthermore, also support the study of safe vector vaccine against ASF with external partners. Research interests
1. New vaccines (protein subunit vaccine, DNA/mRNA vaccine) against significant pig diseases, including from viruses or bacteria.
2. Therapy vaccines or biologicals for canine and feline. Discipline
Bacteriology Bio-manufacturing Bioinformatics Challenge model development Challenge study design Clinical trials – efficacy Epidemiology Formulation technology Immunology – B-cells Immunology – T-cells Immunology – innate Molecular biology Protein biology QC test development Quality assurance Registration Regulation Structural biology Systems biology Virology Host species
Cats Dogs Pigs Pathogen
Bacteria Bacteria›E. coli Bacteria›M. hyo Bacteria›Mycoplasma Bacteria›Salmonella Viruses Viruses›African swine fever virus Viruses›Classical swine fever virus Viruses›Coronavirus Viruses›Porcine circovirus Viruses›Porcine reproductive and respiratory syndrome virus Stage of vaccine development
Adjuvants Antigen discovery and immunogen design Clinical trials Commercialisation Correlates of protection – immunomonitoring Field trials Marketing Pre-clinical trials Vaccine delivery